Search company, investor...
Palatin Technologies company logo

Palatin Technologies

Founded Year




Total Raised


Market Cap


Stock Price


About Palatin Technologies

Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Headquarters Location

4-B Cedar Brook Drive Cedar Brook Corporate Center

Cranbury, New Jersey, 08512,

United States


Missing: Palatin Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Palatin Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Palatin Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Palatin Technologies is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Palatin Technologies Patents

Palatin Technologies has filed 25 patents.

The 3 most popular patent topics include:

  • Peptides
  • G protein coupled receptors
  • Androgens and anabolic steroids
patents chart

Application Date

Grant Date


Related Topics




G protein coupled receptors, Clusters of differentiation, Peptides, Human proteins, Transcription factors


Application Date


Grant Date



Related Topics

G protein coupled receptors, Clusters of differentiation, Peptides, Human proteins, Transcription factors



Latest Palatin Technologies News

New Jersey-based biopharma startup Palatin Technologies raises USD 4.7 million in dilutive funding

Jan 20, 2023

New Jersey-based biopharma startup Palatin Technologies raises USD 4.7 million in dilutive funding By CRANBURY, New Jersey, January 18, 2023  — Palatin Technologies, Inc. (NYSE American: PTN), the biopharmaceutical company developing first-in-class medicines based on the fact that molecules that modulate the activity of the melanocortin receptor system, announced that it  has received approximately USD  4.7 million in non-dilutive funding from New Jersey’s Technology Business Tax Certificate Transfer Program, also known as the Net Operating Loss (NOL) Program. “We are thrilled to take advantage of the New Jersey NOL program, which allows us to turn some state operating losses into tangible working capital today,” said Palatin’s Chief Financial Officer and Chief Operating Officer, Stephen T. Wills. So far, we have received USD 18 million in non-dilutive funding under the NOL program. We are grateful to the NJ Economic Development Authority for assisting us as we continue to research medications for diverse diseases.” The NOL program allows qualifying New Jersey-based technology or biotechnology firms to sell their net operating losses to unrelated successful organizations. This enables eligible technology and biotechnology firms with NOLs to convert their tax losses and credits into cash flows to finance expansion and operations, including R&D. Palatin is a biopharmaceutical firm focused on creating first-in-class medications based on compounds that control the activity of melanocortin receptor systems, including receptor-specific product candidates for treating illnesses with considerable unmet medical needs and economic opportunity. Palatin’s business approach is to create goods and forge marketing partnerships with industry leaders to maximize their economic potential. They have only begun to tap into the efficacy of melanocortin pathways in treating patients after establishing themselves as the first FDA-approved melanocortin agent with Vyleesi® (bremelanotide injectable) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. They are focusing on expanding their commercial platform in North America, assisting commercialization partners overseas, and re-licensing to committed partners in the United States and throughout the world. Their research and development arm expands on their demonstrated success in delivering melanocortin therapy from the lab to the market by leveraging their personal experience to move initiatives in ophthalmic and autoimmune illnesses through the clinical pipeline. We try our  best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know -if there are any discrepancies in any of our published stories, -how we can improve, -what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!

Palatin Technologies Frequently Asked Questions (FAQ)

  • When was Palatin Technologies founded?

    Palatin Technologies was founded in 1986.

  • Where is Palatin Technologies's headquarters?

    Palatin Technologies's headquarters is located at 4-B Cedar Brook Drive, Cranbury.

  • What is Palatin Technologies's latest funding round?

    Palatin Technologies's latest funding round is PIPE - III.

  • How much did Palatin Technologies raise?

    Palatin Technologies raised a total of $26.53M.

  • Who are the investors of Palatin Technologies?

    Investors of Palatin Technologies include RA Capital Management, ProMed Capital, Palo Alto Investors, Vivo Capital, Great Point Partners and 40 more.

  • Who are Palatin Technologies's competitors?

    Competitors of Palatin Technologies include Biolog, PPD, Vernalis, LeadScope, NGM Biopharmaceuticals and 11 more.

Compare Palatin Technologies to Competitors


is a contract research organization that collaborates with R&D departments of biotechnology and biopharmaceutical companies to discover and develop new medicines. The company also engages in its own drug discovery agenda to develop treatments of treat tropical diseases such as malaria.


Martin-Protean is a biotechnology company that determines protein structure using chemical cross-linking and mass spectrometry. Its technology aims to provide insight into protein structure, facilitating drug design and discovery. Its products can be used by the pharmaceutical and biotechnology sectors as well as the NIH, national, and academic labs.

Dialectica srl

Dialectica offers Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases. The mission of Dialectica is to add value to the link between research and pharmaceutical and biotechnology companies that are active in the discovery of therapeutics for brain diseases. Dialectica develops and optimize Neural Stem Cell-based Systems and Assays for drug screening in neurodegenerative diseases.

Oceanit Logo

Oceanit creates solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research.

MI Research

MI Research, Inc. specializes in Biotech instrumentation with excellent visualization capabilities in the area of protein crystal growth and blood viscosity measurements. MI aims to offer fluorescence base protein crystallization prescreening service and biotech instruments like blood viscometers. MI's expertise is in optics and biochemistry.

RealBio Technology

RealBio Technology is working on the commercialization of a cell and tissue culture technology for drug discovery and life science research. The RealBio D4 Culture System facilitates the growth of in vitro cultures that mimic the natural composition, configuration and function of normal and diseased tissue. The design ensures that cells can be cultured with an ideal mixture of gas and nutrients, delivered independently, to promote healthy, consistent growth, improving the culture quality. Results from testing indicate that our system outperforms other available 2D and 3D technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.